NEW YORK (GenomeWeb) – Helena Biosciences said today that it is collaborating with Ghent University to commercialize a glycoprotein-based blood test for chronic liver disease.

Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of serum proteins, and uses this information to diagnose and monitor chronic liver diseases such as hepatic inflammation, fibrosis, and cirrhosis. The test also assesses cirrhosis patients' risk of developing liver cancer within the next five years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.